SCHEMBL369329

SCHEMBL369329

CCC(O)c1nn(Cc2ccc(OC)cc2)cc1C(C)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
AADAT Q8N5Z0 1/20 0.40
SNCA P37840 1/20 0.40
CACNA1G O43497 3/20 0.40
CACNA1H O95180 3/20 0.40
CACNA1I Q9P0X4 3/20 0.40
NPC1 O15118 3/20 0.39
MEN1 O00255 2/20 0.39
RAB9A P51151 2/20 0.39
GAA P10253 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HDAC1 Q13547 1/20 0.39
CMA1 P23946 1/20 0.38
KLKB1 P03952 1/20 0.37
LDHA P00338 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
CYP19A1 P11511 1/20 0.36
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370871 0.86 LDHA (0.42) KMT2AL3MBTL1AADATSNCACACNA1G
SCHEMBL12482396 0.85 KMT2A (0.41) KMT2AL3MBTL1AADATSNCACACNA1G
SCHEMBL368607 0.85 CACNA1G (0.41) KMT2AL3MBTL1AADATSNCACACNA1G
SCHEMBL370457 0.85 KLKB1 (0.48) KMT2AL3MBTL1AADATSNCACACNA1G
SCHEMBL370870 0.84 CACNA1G (0.40) KMT2AL3MBTL1AADATSNCACACNA1G
SCHEMBL369532 0.84 KMT2A (0.37) KMT2AL3MBTL1AADATCACNA1GCACNA1H
SCHEMBL369533 0.83 CACNA1G (0.39) KMT2AL3MBTL1AADATSNCACACNA1G
SCHEMBL370448 0.80 L3MBTL1 (0.48) KMT2AL3MBTL1AADATSNCACACNA1G
SCHEMBL15182553 0.79 KMT2A (0.46) KMT2AL3MBTL1AADATSNCACACNA1G
SCHEMBL15182579 0.78 KMT2A (0.43) KMT2AL3MBTL1AADATSNCACACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 KMT2A 1638/4885L3MBTL1 4579/4885AADAT 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.